AAN: Apomorphine May Shorten 'Off' Time for Parkinson's Patients
Study finds apomorphine cuts the time until levodopa kicks in for those with advanced disease
MONDAY, April 24, 2017 (HealthDay News) -- Apomorphine may help patients with advanced Parkinson's disease when levodopa stops working, according to a study presented at the annual meeting of the American Academy of Neurology, held from April 22 to 28 in Boston.
For this new 12-week phase 3 study, Regina Katzenschlager, M.D., a guest professor at the Medical University of Vienna, and colleagues randomly assigned 107 patients with advanced Parkinson's disease to either infusions of apomorphine or a placebo. Daily infusions were given over 14 to 18 hours via a small portable pump.
Patients given apomorphine had, on average, 2.5 hours less "off" time, compared with those receiving a placebo, whose reduction in "off" time averaged only 30 minutes. The improvement was seen within the first week of treatment, and patients on apomorphine experienced an increase in "on" time without the dyskinesia often observed with levodopa, the researchers reported.
When patients were asked to evaluate their treatments, those who received apomorphine gave their treatment higher scores at week 12 than those who received a placebo, Katzenschlager's team said. Among patients receiving apomorphine, 71 percent felt an improvement, compared with 18 percent of those who received a placebo. Nineteen percent of the patients receiving apomorphine worsened, compared with 45 percent of those on a placebo. Apomorphine was well tolerated and no serious side effects were seen, the researchers added.
The study was funded by British-based Britannia Pharmaceuticals, the manufacturer of apomorphine.